Healthcare & Life Sciences AI Solutions.

---

Business Objective: Accelerate prior authorization processing by automating clinical document review, payer-policy matching, and authorization workflow preparation.

Target Outcome: Designed to reduce manual review time by up to 90% in eligible workflows; actual results depend on case complexity, data quality, payer rules, and validation.

A multi-agent orchestration architecture that processes prior authorization requests, extracts relevant clinical evidence, retrieves applicable payer policies, and evaluates requests against configured criteria. Straightforward cases can be prepared for streamlined processing, while ambiguous or incomplete cases are routed to qualified clinical reviewers for a final decision.

1. Request Ingestion & Document Processing

Authorization requests enter through supported HL7 v2 ADT/ORM messages, API integrations, or uploaded clinical documents stored in Google Cloud Storage. Document AI processes supported documents to extract patient demographics, provider details, and relevant clinical information.

2. Clinical Data Extraction

A clinical language-model agent analyzes physician notes and supporting records to identify diagnoses, requested procedures, relevant medical history, and documented conservative treatments. Extracted information is structured for downstream evaluation, with source references retained where supported.

3. Payer Guideline Retrieval (RAG)

A retrieval-augmented generation (RAG) component searches an approved knowledge repository containing applicable payer medical policies and authorization criteria. Vertex AI Search or Vertex AI Vector Search can support retrieval, depending on the selected implementation.

4. Criteria Evaluation & Gap Analysis

A decision-support agent compares the extracted clinical evidence with the retrieved policy criteria. It identifies satisfied requirements, missing documentation, and conflicting information, producing a structured assessment for review rather than relying solely on unrestricted model judgment.

5. Workflow Orchestration & System Writeback

Requests with complete evidence are prepared for the configured authorization workflow. Incomplete or ambiguous cases are routed to an appropriate clinical review queue with a gap-analysis summary. Where supported and authorized, the system can integrate with payer or provider platforms to transmit status updates or prepare standardized transaction data.

• Document AI: Clinical document processing and information extraction.
• Cloud Healthcare API: Healthcare data interoperability and supported FHIR/HL7 workflows.
• Vertex AI: Model inference, orchestration, and AI application development.
• Vertex AI Search / Vector Search: Retrieval of approved payer policies and clinical criteria.
• Cloud Storage: Secure storage for incoming documents and supporting files.
• Cloud Run: API services and backend processing.
• Pub/Sub and Cloud Tasks: Asynchronous processing and workflow coordination, where required.
• BigQuery: Operational analytics, processing metrics, and audit reporting, subject to data-governance requirements.
• Identity and Access Management (IAM): Role-based access and service permissions.

• Apply appropriate access controls and protection for sensitive health information.
• Maintain traceability between clinical evidence, retrieved policy criteria, and generated assessments.
• Require qualified human review for ambiguous cases and decisions that require clinical judgment.
• Validate payer-specific rules, transaction formats, and interoperability before production use.
• Treat automated approval or denial as a separately governed capability requiring explicit authorization, compliance review, and end-to-end testing.

• Reduce repetitive manual document review.
• Accelerate identification of missing clinical evidence.
• Improve consistency in applying payer-specific criteria.
• Help reviewers prioritize complex or incomplete requests.
• Improve visibility into authorization workflow status and bottlenecks.
• Support scalable processing while retaining appropriate clinical oversight.

Business Objective: Help healthcare organizations identify patients who may be at elevated risk of hospital readmission or chronic disease deterioration by combining clinical, claims, pharmacy, and care-utilization data to support proactive care management.

Target Outcome: Aims to support earlier intervention and reduce potentially preventable admissions. A 25% reduction is a target that must be validated through measured clinical and operational outcomes; actual results depend on the patient population, intervention effectiveness, and care delivery workflows.

A population-level analytics and AI architecture that consolidates patient information, engineers' predictive features, calculates risk scores, and generates prioritized care-management recommendations. Predictive models identify patients who may need additional attention, while a generative AI component summarizes contributing risk factors and drafts suggested interventions for review by authorized care teams.

1. Data Ingestion & Harmonization

Clinical data, claims, admission-discharge-transfer (ADT) events, pharmacy records, and other approved sources are ingested through configured batch or streaming pipelines. Healthcare Data Engine (HDE), where available and appropriate, or supported healthcare interoperability services can map data into a unified FHIR-based representation.

2. Feature Engineering & Data Preparation

Dataflow pipelines and BigQuery transformations prepare relevant features, such as recent admissions, chronic condition history, available laboratory trends, missed appointments, medication-related indicators, and approved social determinants of health. Data-quality checks address missing values, inconsistent identifiers, and data freshness before scoring.

3. Predictive Risk Scoring

A scheduled BigQuery ML workflow or a deployed model evaluates eligible patient records to estimate a defined outcome, such as 90-day readmission risk or chronic disease deterioration. Model outputs are used to rank patients for further assessment, with thresholds calibrated and evaluated against the intended population.

4. Risk Driver Analysis & Intervention Planning

For patients prioritized by the risk model, a generative AI component summarizes the available risk indicators and drafts potential care-management actions, such as scheduling follow-up, reviewing medication adherence, or arranging a telehealth appointment. Recommendations are grounded in available records and routed to qualified care staff for review before action.

5. Care Manager Dashboard & Workflow Integration

Risk scores, contributing factors, data freshness indicators, and suggested interventions are presented through a Looker dashboard or configured care-management interface. Care managers can review prioritized patient lists, document follow-up actions, and track intervention status through supported workflows.

• Healthcare Data Engine (HDE) / Healthcare Interoperability Services: Harmonization of supported healthcare data sources, where available.
• Cloud Healthcare API (FHIR): FHIR-based exchange and management of supported clinical data.
• BigQuery: Centralized analytics, patient-level feature tables, and reporting datasets.
• BigQuery ML: Predictive modeling and scheduled risk scoring where the selected model is supported.
• Dataflow: Batch and streaming data transformation and feature preparation.
• Vertex AI: Optional model serving and generative AI orchestration for risk summaries and intervention drafts.
• Looker: Population-level dashboards and care-manager reporting.
• Cloud Scheduler / Workflows: Scheduled scoring and orchestration, where required.
• IAM, Cloud Logging & Audit Controls: Access management, monitoring, and traceability for sensitive health data.

• Validate model performance, calibration, and fairness across relevant patient groups.
• Define the prediction target and time horizon clearly, and monitor model drift.
• Use only authorized, relevant patient data and apply appropriate access controls.
• Present risk scores as decision-support signals, not definitive predictions of an individual patient's outcome.
• Require qualified clinical review before interventions, medication changes, or care-plan decisions.
• Monitor intervention completion and clinical outcomes to evaluate whether the program improves care.

• Identify patients who may benefit from earlier care-team attention.
• Support proactive outreach and follow-up planning.
• Help care managers prioritize limited resources using consistent risk indicators.
• Improve visibility into population-level trends and care gaps.
• Reduce manual effort involved in assembling patient risk summaries.
• Support measurable evaluation of care-management interventions and outcomes.

Business Objective: Accelerate early-stage drug discovery by combining biological data analysis, protein-structure modeling, generative chemistry, and computational screening to help researchers identify promising therapeutic targets and candidate molecules.

Target Outcome: Designed to shorten parts of the early discovery workflow by prioritizing research hypotheses and candidate compounds more efficiently. Any claim of reducing discovery timelines by years must be validated against a defined baseline and measured research outcomes.

A computational drug-discovery pipeline that integrates multi-omics data, scientific literature, protein-structure prediction, generative molecular design, and high-throughput virtual screening. The system ranks candidate targets and molecules using configurable scientific criteria, enabling computational chemists and biologists to focus on promising candidates for further evaluation.

1. Scientific Data Integration & Knowledge Graph Construction

Relevant biological datasets, public scientific literature, patent information, and available assay results are ingested from approved sources. Big Query supports structured data storage and analysis, while a knowledge graph or graph-based retrieval layer can connect genes, proteins, pathways, diseases, compounds, and experimental evidence.

2. Target Selection & Protein Structure Modeling

Researchers select a disease-associated protein or pathway for investigation. Protein structures are retrieved from validated scientific resources or predicted using an appropriate structure-prediction model, such as AlphaFold 3 where access and usage conditions permit. Structure quality, biological context, and uncertainty are assessed before downstream screening.

3. Generative Molecule Design

A molecular-design component proposes candidate compounds using suitable generative models and chemical representations such as SMILES. Candidate generation can be guided by defined objectives, including predicted binding affinity, chemical validity, synthesizability, selectivity, and toxicity-related risk indicators. Generated molecules remain computational hypotheses until experimentally evaluated.

4. High-Throughput Virtual Screening

Google Cloud Batch or other suitable high-performance computing resources can execute parallel molecular docking and related simulations. Tools such as AutoDock Vina may estimate plausible binding poses and scoring functions for candidate molecules against the selected protein structure. Results are recorded alongside model settings and relevant run metadata.

5. Candidate Ranking & Researcher Review

Screening results are consolidated in Big Query or an appropriate research data store. A ranking component prioritizes candidates using configured criteria, potentially combining docking scores, chemical properties, novelty checks, and predicted safety indicators. Researchers review the evidence and select candidates for follow-up simulations, synthesis, and laboratory validation.

• Big Query: Storage, integration, and analysis of structured biological and screening data.
• Vertex AI: Hosting or orchestrating supported custom models and molecular-design workflows.
• Google Cloud Batch: Parallel execution of computational screening and simulation jobs.
• Google Kubernetes Engine (GKE): Optional orchestration for containerized research workloads where needed.
• Cloud Storage: Storage for molecular structures, protein files, simulation outputs, and research artifacts.
• AlphaFold 3 / Approved Structure-Prediction Resources: Protein-structure modeling, subject to access, deployment, and usage conditions.
• AutoDock Vina / Molecular Docking Tools: Virtual screening and approximate ligand-binding pose evaluation.
• Cloud Logging & Monitoring: Job status, failures, resource utilization, and operational monitoring.
• IAM & Research Data Governance: Controlled access to datasets, model artifacts, and proprietary research information.

• Track the provenance, licensing, and quality of biological datasets and scientific references.
• Validate protein structures, target relevance, and molecular representations before screening.
• Treat docking scores and predicted binding affinity as computational estimates, not proof of biological activity.
• Evaluate candidate novelty, chemical feasibility, selectivity, and predicted toxicity using suitable validated methods.
• Preserve reproducibility through versioned datasets, model configurations, and simulation parameters.
• Require expert review and experimental validation before making development or safety decisions.

• Reduce manual effort in early-stage target and compound prioritization.
• Screen larger candidate sets through parallel computational workflows.
• Integrate biological evidence and molecular analysis into a more consistent research process.
• Help researchers prioritize compounds for further computational or laboratory investigation.
• Improve traceability of candidate selection and screening results.
• Support scalable computational research using cloud-based infrastructure.

Business Objective: Accelerate regulatory submission preparation by using AI-assisted document processing, structured evidence retrieval, and source-grounded drafting to help pharmaceutical and biotechnology teams prepare electronic Common Technical Document (eCTD) content for regulatory review.

Target Outcome: Aims to reduce submission authoring time by up to 40% by streamlining document extraction, evidence gathering, and initial drafting. This target requires validation; actual results depend on submission complexity, source-document quality, review requirements, and regulatory standards.

An AI-assisted regulatory authoring architecture that ingests clinical, nonclinical, and Chemistry, Manufacturing, and Controls (CMC) documentation; extracts relevant evidence; and generates structured draft content aligned with selected eCTD module templates. A retrieval-augmented generation (RAG) component grounds draft statements in source material, while a verification workflow checks references and flags unsupported claims for Regulatory Affairs review.

1. Source Document Ingestion

Clinical Study Reports (CSRs), supporting tables, CMC documents, and other approved regulatory source files are uploaded to designated Google Cloud Storage buckets. Access permissions and document metadata are managed according to the organization's data-governance requirements.

2. Document Extraction & Indexing

Document AI processes supported files to extract text, tables, headings, and other relevant content. Extracted information is organized and indexed using a configured retrieval service, such as Vertex AI Search, so users and downstream agents can locate evidence across large document collections.

3. Intelligent Regulatory Authoring

A generative AI component uses approved eCTD templates, relevant source evidence, and drafting instructions to produce initial content for selected modules or sections—for example, a clinical efficacy summary. Drafts follow defined structure and terminology requirements, with source information supplied through retrieval rather than relying solely on model-generated knowledge.

4. Evidence Grounding & Verification

A verification component checks whether important statements in the generated draft are supported by the identified source documents. It validates available citations, document references, table identifiers, and section references, and flags unsupported statements, conflicting values, missing evidence, or unresolved questions. Citation verification should be based on actual source locations rather than generated hyperlinks alone.

5. Review, Export & Submission Preparation

Draft content and verification findings are exported into supported Word or PDF formats for review by Regulatory Affairs, clinical, and CMC subject-matter experts. Reviewers resolve flagged issues, approve the final wording, and complete required formatting, quality checks, and publishing steps using the organization's validated regulatory submission process.

• Cloud Storage: Controlled storage for source documents, extracted artifacts, and draft outputs.
• Document AI: Extraction of text, tables, and structured information from supported documents.
• Vertex AI: Generative model inference and AI workflow development.
• Vertex AI Search: Retrieval of relevant source evidence from indexed regulatory documentation.
• Cloud Run: Backend APIs and document-processing orchestration for the eCTD workflow.
• Cloud Logging & Monitoring: Processing observability, error tracking, and operational monitoring.
• IAM & Audit Controls: Access restrictions and traceability for sensitive regulatory and research documents.

• Apply document-level access controls and protect confidential clinical, manufacturing, and regulatory information.
• Preserve source provenance and maintain traceability from drafted claims to supporting documents.
• Verify citations, table references, numerical values, and cross-document consistency.
• Flag conflicting, incomplete, or unsupported evidence instead of silently filling gaps.
• Apply approved templates, terminology standards, version controls, and review procedures.
• Require qualified Regulatory Affairs and subject-matter experts to review and approve all submission content.
• Validate the complete document workflow, including export, formatting, and quality checks, before production use.

• Reduce repetitive evidence gathering and initial drafting effort.
• Help regulatory teams navigate large collections of clinical and CMC documentation.
• Improve traceability between submission statements and source evidence.
• Support more consistent use of approved eCTD templates and terminology.
• Identify missing evidence and document inconsistencies earlier in the review process.
• Enable regulatory professionals to focus more time on scientific accuracy, compliance, and final submission quality.

Business Objective: Help pharmaceutical manufacturers, healthcare distributors, and logistics providers protect temperature-sensitive biologics by monitoring shipment conditions, predicting potential cold-chain disruptions, and coordinating timely responses throughout transportation.

Target Outcome: Designed to reduce the risk of biologic spoilage, improve shipment visibility, and support cold-chain compliance. Actual results depend on sensor coverage, product-specific storage requirements, alert response times, and logistics integration.

An IoT-integrated supply-chain monitoring and orchestration architecture that combines live shipment telemetry, stream analytics, predictive risk assessment, and logistics workflow automation. Sensor readings and shipment-location data are evaluated against approved product-specific temperature and handling requirements. When an excursion or disruption risk is detected, the system alerts responsible teams and can recommend corrective actions or initiate pre-authorized logistics workflows.

1. IoT Telemetry Ingestion

Smart shipping containers and connected data loggers transmit available sensor readings, including temperature, humidity, shock, and GPS location. Devices publish data through supported MQTT gateways or IoT integrations, with Pub/Sub distributing incoming events to downstream processing services. Sensor identity, timestamps, calibration status, and shipment association are validated where supported.

2. Real-Time Stream Processing

Dataflow processes incoming telemetry and compares measurements with the approved storage and transportation limits for the specific biologic product. The workflow identifies threshold breaches, missing readings, unusual fluctuations, and prolonged periods outside acceptable conditions. Alert rules account for product-specific excursion allowances and handling procedures.

3. Predictive Cold-Chain Risk Assessment

A predictive model hosted through Vertex AI can estimate the likelihood of a potential temperature excursion using available sensor trends, shipment location, route information, weather data, and known transportation delays. Risk scores help operations teams prioritize shipments that may require intervention. Predictions are treated as risk indicators rather than guarantees of future conditions.

4. Logistics Orchestration & Corrective Action

When an excursion or elevated risk is identified, the orchestration service generates an alert and recommends an appropriate response, such as contacting the carrier, arranging an approved storage facility, inspecting refrigeration equipment, or coordinating replenishment of a qualified cooling system. Where authorized and supported by connected logistics APIs, the system can initiate predefined rerouting or intervention workflows. Safety-critical actions remain subject to approved operating procedures and responsible personnel.

5. Chain of Custody, Reporting & Delivery Verification

Shipment events—including recorded temperatures, location updates, alerts, interventions, and delivery milestones—are stored in BigQuery or another configured audit data store. The system produces a shipment history and can generate a cold-chain compliance report based on available sensor records, applicable product limits, and documented handling actions. Authorized personnel review exceptions and confirm whether the shipment meets the relevant acceptance requirements.

• Pub/Sub: Event ingestion and asynchronous distribution of shipment telemetry.
• Dataflow: Real-time stream processing, threshold evaluation, and telemetry transformation.
• Vertex AI: Predictive modeling and shipment risk assessment, where a validated model is configured.
• Big Query: Shipment event history, analytics, exception records, and audit reporting.
• Cloud Run: Backend APIs, alert processing, and logistics orchestration services.
• Cloud Storage: Storage for supporting shipment documents and generated reports.
• Cloud Monitoring & Logging: Operational monitoring, alert tracking, and service diagnostics.
• IAM & Audit Controls: Access restrictions, service permissions, and traceability.

• Configure temperature limits and permitted excursion conditions for each applicable biologic product.
• Validate sensor accuracy, calibration, timestamp integrity, connectivity, and shipment-to-device mapping.
• Define alert thresholds, escalation contacts, response times, and fallback procedures for missing telemetry.
• Require approved operating procedures for rerouting, cooling-system interventions, and product disposition.
• Preserve traceable records of temperature excursions, alerts, corrective actions, and delivery events.
• Do not automatically declare a biologic safe or unusable based solely on a predictive score; qualified personnel must assess excursions against product-specific stability guidance.
• Validate the complete workflow against applicable quality systems and cold-chain requirements before production use.

• Improve visibility into temperature-sensitive shipments throughout transportation.
• Identify potential cold-chain excursions earlier using sensor data and risk indicators.
• Help reduce avoidable spoilage and shipment disruption.
• Support faster coordination among carriers, depots, and logistics teams.
• Strengthen documentation of shipment conditions and corrective actions.
• Simplify preparation of cold-chain monitoring and compliance reports.
• Support more reliable transportation workflows for vaccines, biologics, and other temperature-sensitive therapies.